
Epicentre Technologies Corporation (AKA: Epicentre Biotechnologies) Profile last edited on: 11/13/2023
CAGE: 03WG6
UEI: ----------
Business Identifier: Biological Products, Except Diagnostic Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
5602 Research Park Boulevard Suite 200
Madison, WI 53719
Madison, WI 53719
(608) 258-3080 |
techhelp@epicentre.com |
www.epibio.com |
Location: Single
Congr. District: 02
County: Dane
Congr. District: 02
County: Dane
Public Profile
Epicentre(R) Biotechnologies, founded in 1987, uses its expertise in enzyme manufacturing to produce innovative kits for life science research. The kits and reagents manufactured by Epicentre contribute to breakthrough studies in genomics and transcriptomics. Products are available for DNA and RNA sequencing, gene expression analysis, DNA and RNA purification, PCR and RT-PCR, cloning, in vitro transcription, and microbial genomics. Epicentre's products are used worldwide in academic, commercial, and government laboratories in diverse applications, including basic research, drug discovery, cancer research, infectious disease research, microbiology, and personalized medicine. On January 10, 2011, Epicentre was acquired by Illumina, Inc. The company continues to operate as a wholly owned subsidiary of Illumina from its headquarters in Madison, Wisconsin.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 2 | DOE | $1,349,962 | |
Project Title: Advanced Laser Ultrasonic Sensor for Fuel Rod Characterization | ||||
2000 | 1 | NIH | $100,000 | |
Project Title: An RNA Polymerase for Synthesis of Capped RNAs | ||||
2000 | 1 | DOE | $100,000 | |
Project Title: Rapid, Direct Sequencing of Bacterial Artificial Chromosome Clones Using Transposomes-tm | ||||
1990 | 1 | NIH | $50,000 | |
Project Title: Characterization of the potential new antimicrobial agent |
Key People / Management
Gary Dahl -- President
Linda A Guarino
Jerome Jendrisak
Marvin B Klein
Linda A Guarino
Jerome Jendrisak
Marvin B Klein
Company News
There are no news available.